Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
63. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphos-pholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997— 2002.
64. Pierangeli SS, Espinola RG, Liu X, et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245— 250.
65. Del Papa N, Sheng YH, Raschi E, et al. Human 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-2glycoprotein I antibodies. J Immunol 1998; 160: 5572— 5578.
66. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by anti-phospholipid (anti-?2-glycoprotein I) antibodies: effect on the pro-adhesive and proin-flammatory phenotype. Arthritis Rheum 2001; 44: 2870—2878.
67. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495—3500.
68. Александрова ЕН, Новиков АА., Решет-няк ТМ, Клюквина НГ, Решетняк ДВ, Самсонов МЮ, Насонов ЕЛ. Растворимые молекулы адгезии при антифосфолипидном синдроме, связанном с системной красной волчанкой, и первичном антифосфолипидном синдроме. Терапевт. архив, 2002; 5; 23—27.
69. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospho-lipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55— 64.
70. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89:1—2.
71. Dobado-Berrios F-M, Lopez-Pedrera C, Velasco F, Cuadrado M-J. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 2001; 44: 2467—2476.
72. Amengual O, Atsumi T, Khamashta MA. Tissue factor in the antiphospholipid syndrome: shifting the focus from coagulation to endotheli-um. Rheumatology 2003; 43: 1—3.
73. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206—210.
74. Kornberg A, Renaudineau Y, Blank M, Youinou P, Shoenfeld Y. Anti-?2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2000; 2 (Suppl 1): 27—31.
75. Cuadrado MJ, Buendia P, Lopez-Pedrera C, et al. Increased tissue factor expression in monocytes from patients with antiphospholipid syndrome depens on NFkB activation.
SHS-OOO4.qxd 21.11.2006 16:56 Page 104"
04
Насонов Е.Л. Антифосфолипидный синдром.
ACR/ARHP Annual Acientific Meeting 2003; October 24—28, 322 (abst).
76. Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, Passaleva A, Prisco D, Abbate R. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythe-matosus. Lupus 1996; 5: 206—211.
77. Visvanathan S, Geczy CL, Harmer JA, McNeil HP. Monocyte tissue factor induction by activation of ?2-glycoprotein-I-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies. J Immunol. 2000; 165: 2258—2262.
78. Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, Ordinas A. Hypercoa-gulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s. Arterioscler Thromb Vasc Biol 1996; 16: 1319— 1326.
79. Dunoyer-Geindre S, De Moerloose P, Galve-De Rochemonteix B, et al. NF-kB is an essential intermediate in the activation of endothelial cells by anti-beta2-glycoprotein I antibodies. Thromb Haemost 2002; 88: 851—857.
80. Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to ?2-glyco-protein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 653—656.
81. Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospho-lipid syndrome. Br JHaematol 2001; 114:375— 379.
82. Andree HAM, Hermens WT, Hemker HC, Willems GM. Displacement of factor Va by annexin V. In: Andree HAM, ed. Phospholipid Binding and Anticoagulant Action of Annexin V. Maastricht, The Netherlands: Universitaire Pers Maastricht 1992: 73—85.
83. Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, Lockwood CJ. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566—1572.
84. Rand JH, Wu XX, Guller S, Scher J, Andree HAM, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-Vlevels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177: 918—923.
